TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26145489

Group type: EXPERIMENTAL
Intervention: Individualized feedback‐based virtual reality exercise (IFVRG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Group-based exercise (GG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Both groups (IFVRG and GG)
Number of subjects: 54
Study: 23428998

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Alteplase in patients with baseline body temperature of 37.0°C or higher
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Alteplase in patients with baseline body temperature below 37.0°C
Number of subjects: 647
Study: 20806420

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 43
Study: 20001460

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 19
Study: 17320025

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active vitamin D metabolites (calcitriol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive therapy initiated in the immediate posttransplantation period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone mass measurement and treatment of osteoporosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral or parenteral bisphosphonates and calcitriol
Number of subjects: 0
Study: 15314341

Group type: EXPERIMENTAL
Intervention: Constipation reduction program (experimental group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 61
Study: 11501230

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (Crestor); specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable; control group not mentioned.
Number of subjects: 0
Study: 9386697

Group type: EXPERIMENTAL
Intervention: Preconditioning (two cycles of 2-minute occlusion of the vena cava and aorta followed by 3 minutes of reperfusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preconditioning
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no preconditioning)
Number of subjects: 30
Study: 8143996

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg, three times daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg, three times daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cisapride (both doses)
Number of subjects: 42
Study: 3422091

Group type: EXPERIMENTAL
Intervention: Adolescents with T cell ALL
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Adolescents with non-T cell ALL
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Adolescents with early pre-B ALL
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Adolescents with pre-B ALL
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Adolescents with T ALL
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Adolescents with non-T, non-B ALL
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Adolescents with leukemic cells
Number of subjects: 425
Study: 30188180

Group type: EXPERIMENTAL
Intervention: Collaborative algorithm for diabetes management during Ramadan
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 62
Study: 28328389

Group type: EXPERIMENTAL
Intervention: Tablet-based hearing screening method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional audiometry
Number of subjects: 30
Study: 26203761

Group type: EXPERIMENTAL
Intervention: CRT
Number of subjects: 258

Group type: COMPARATOR
Intervention: CRT + cetuximab
Number of subjects: 258
Study: 23885614

Group type: EXPERIMENTAL
Intervention: Moxibustion at Shenshu (BL 23) and Guanyuan (CV 4) for 15 min once daily for 5 weeks after training.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no moxibustion).
Number of subjects: 24
Study: 20958974

Group type: EXPERIMENTAL
Intervention: Allicor (time-released garlic powder tablets)
Number of subjects: 51
Study: 17662639

Group type: EXPERIMENTAL
Intervention: Eccentric calf muscle training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Therapeutic ultrasound
Number of subjects: 16
Study: 16647533

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori presence in the middle ear, tonsillar and adenoid tissues
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (normal otologic findings)
Number of subjects: 22
Study: 14655264

Group type: EXPERIMENTAL
Intervention: GlucoWatch Biographer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GlucoWatch Biographer (if ceased to be effective after age 17)
Number of subjects: 18
Study: 10985062

Group type: EXPERIMENTAL
Intervention: Organ-selective thyrotoxicosis (19 patients)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Subclinical thyrotoxicosis (14 patients)
Number of subjects: 33
Study: 8834417

Group type: EXPERIMENTAL
Intervention: risperidone (mean dose, 7.4 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: haloperidol (7.6 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: methotrimeprazine (100 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 62

Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 62
Study: 1573365

Group type: EXPERIMENTAL
Intervention: Anti-smoking advice (intervention)
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 1445
Study: 6363970

Group type: EXPERIMENTAL
Intervention: Central anticholinergic therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Peripheral anticholinergic therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (peripheral anticholinergic)
Number of subjects: 9
Study: 31395071

Group type: EXPERIMENTAL
Intervention: MR technology-assisted group (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional C-arm fluoroscopy group (group B)
Number of subjects: 40
Study: 30094695

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Both interventions (Methadone and Buprenorphine/Naloxone)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Cocaine users and injection drug users
Number of subjects: 699

Group type: COMPARATOR
Intervention: Hispanics (vs. whites) and those treated in clinics on the West Coast (vs. East)
Number of subjects: 699
Study: 27094111

Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 746

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 746
Study: 25617577

Group type: EXPERIMENTAL
Intervention: 600 mg/day of alpha lipoic acid (ALA) for twelve weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21737518

Group type: EXPERIMENTAL
Intervention: Combination of albuminuria and estimated glomerular filtration rate (eGFR) for CKD diagnosis
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Specific chronic nephropathy
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Undetermined chronic nephropathy
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: CKD Stages 1, 2, 3, and 4
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Lone low eGFR and lone microalbuminuria
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: eGFR and albuminuria
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Follow-up studies
Number of subjects: 524
Study: 19337246

Group type: EXPERIMENTAL
Intervention: Esophageal capsule endoscopy (ECE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 120
Study: 17786387

Group type: EXPERIMENTAL
Intervention: Intravenous ATP infusions at doses of 20 microg kg(‐1) min(‐1), 25-40 microg kg(‐1) min(‐1), and 45-50 microg kg(‐1) min(‐1)
Number of subjects: 51
Study: 15612969

Group type: EXPERIMENTAL
Intervention: Purified trivalent split-virus vaccine injections
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 11642001

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise program
Number of subjects: 0
Study: 9853844

Group type: EXPERIMENTAL
Intervention: Recombinant follicle stimulating hormone (rFSH, Puregon)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG, Humegon)
Number of subjects: 89
Study: 7983255

Group type: EXPERIMENTAL
Intervention: Scotchbond
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Gluma
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Clearfil New Bond
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Scotchbond 2
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Tenure
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Tripton
Number of subjects: 346

Group type: COMPARATOR
Intervention: Bayer exp. 1
Number of subjects: 346

Group type: COMPARATOR
Intervention: Bayer exp. 2
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond System
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose
Number of subjects: 346
Study: 2904312

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg every 8 hours)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prazosin (5 mg every 8 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30402489

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 45
Study: 27344670

Group type: EXPERIMENTAL
Intervention: PBM application at the donor site using a 60 J/cm(2) dose
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PBM application using a 30 J/cm(2) dose
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 51
Study: 25050827

Group type: EXPERIMENTAL
Intervention: Exercise condition (PACER task, aerobic fitness assessment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no treatment)
Number of subjects: 0
Study: 21856022

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/d
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21903567

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive systems with different dentin conditioning times; groups divided based on conditioning time and adhesive system used (n = 10 per group).
Number of subjects: 60
Study: 18173628

Group type: EXPERIMENTAL
Intervention: Near pupil responses (NPR) classified as normal, reduced, or absent
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: NPR
Number of subjects: 90
Study: 16602839

Group type: EXPERIMENTAL
Intervention: mezlocillin (3 x 2 g/d)
Number of subjects: 105

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study: 12588573

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including staff and resident education on fall prevention, advice on environmental adaptations, progressive balance and resistance training, and hip protectors
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 981
Study: 10913939

Group type: EXPERIMENTAL
Intervention: rhEPO (40 U/kg at a constant infusion rate for 30 min, starting 15 min before TRH injection)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: rhEPO plus TRH
Number of subjects: 16

Group type: COMPARATOR
Intervention: rhEPO
Number of subjects: 16

Group type: COMPARATOR
Intervention: TRH
Number of subjects: 16
Study: 9044441

Group type: EXPERIMENTAL
Intervention: Estrogen replacement treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Progestin
Number of subjects: 38
Study: 1573788

Group type: EXPERIMENTAL
Intervention: Gastrectomy with extended lymph node dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional gastrectomy
Number of subjects: 0
Study: 4054198

Group type: EXPERIMENTAL
Intervention: Meclonazepam 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meclonazepam 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meclonazepam 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30867552

Group type: EXPERIMENTAL
Intervention: Smoked cocaine dependence (SCD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Insufflated cocaine addiction
Number of subjects: 25
Study: 29847145

Group type: EXPERIMENTAL
Intervention: Arthroscopic‐assisted repair of the medial patellofemoral ligament (MPFL) with anchors, 4 weeks with a soft cast splint, and physical therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Knee brace (KB group) for 4 weeks and physical therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Arthroscopic‐assisted repair of the medial patellofemoral ligament (MPFL)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Knee brace (KB group)
Number of subjects: 74
Study: 27181790

Group type: EXPERIMENTAL
Intervention: Bremelanotide (BMT) 1.25/1.75 mg
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 24835837

Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) screening (left hand, right hand, feet)
Number of subjects: 26
Study: 21447539

Group type: EXPERIMENTAL
Intervention: Bupropion + education for internet use (EDU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo + education for internet use (EDU)
Number of subjects: 50
Study: 20075367

Group type: EXPERIMENTAL
Intervention: Randomized biomarker-stratified designs
Number of subjects: 0
Study: 18823468

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120
Study: 16600937

Group type: EXPERIMENTAL
Intervention: [6S]-5-Methyltetrahydrofolate (416 microg/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Folic acid (400 microg/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 14684754

Group type: EXPERIMENTAL
Intervention: Flanders strain of flax seed (low in lignan and high in alpha-linolenic acid)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Linola 989 strain of flax seed (high in lignan and low in alpha-linolenic acid)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: AC Linora strain of flax seed (intermediate in both lignan and alpha-linolenic acid)
Number of subjects: 35
Study: 10760553

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dysthymic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major depressive patients
Number of subjects: 0
Study: 8814098

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 700 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 600 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 500 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 300 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1306479

Group type: EXPERIMENTAL
Intervention: Argon laser pan retinal photocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diode laser pan retinal photocoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 0
Study: 2997092

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (prednisone for six days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No corticosteroid therapy
Number of subjects: 60
Study: 30246214

Group type: EXPERIMENTAL
Intervention: Polyolefin cast
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fibreglass cast
Number of subjects: 80
Study: 28943228

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 25683105

Group type: COMPARATOR
Intervention: 100% portion size (677 kcal)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 150% portion size (1015 kcal)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200% portion size (1353 kcal)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 250% portion size (1691 kcal)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Food responsiveness
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Satiety responsiveness
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Weight status
Number of subjects: 100
Study: 23215944

Group type: EXPERIMENTAL
Intervention: Post Acc
Number of subjects: 10

Group type: COMPARATOR
Intervention: Post Acc +PC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post Acc and Post Acc +PC
Number of subjects: 10
Study: 21517867

Group type: EXPERIMENTAL
Intervention: Universal school-based prevention program (13 sessions)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 417
Study: 18410562

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (strains E/N, Oxy and Pen) administered at 2 x 10(10) colony forming units, orally twice daily during antibiotic treatment
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (strains E/N, Oxy and Pen)
Number of subjects: 240
Study: 16934074

Group type: EXPERIMENTAL
Intervention: Bruise alone
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Sore arm alone
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Fatigue alone
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Donor reaction alone
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Donor reaction, fatigue, and sore arm together
Number of subjects: 1000
Study: 15588134

Group type: EXPERIMENTAL
Intervention: Breathing room air
Number of subjects: 7

Group type: COMPARATOR
Intervention: Breathing 12% O2 (hypoxic condition)
Number of subjects: 7
Study: 12790964

Group type: EXPERIMENTAL
Intervention: Standard medical injection sclerotherapy (Group 1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NP‐led advice, information and bowel habit retraining (Group 2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 25
Study: 9059471

Group type: EXPERIMENTAL
Intervention: Fenoterol (15 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8229491

Group type: EXPERIMENTAL
Intervention: AS-1 preserved PRBC
Number of subjects: 16

Group type: COMPARATOR
Intervention: CPDA-1 preserved PRBC
Number of subjects: 16
Study: 3875955

Group type: EXPERIMENTAL
Intervention: Bedrest with additional intravenous infusion of glucose
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bedrest
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Maternal transcutaneous nerval stimulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Maternal oxygen inhalation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Oral long-term tocolysis
Number of subjects: 49
Study: 31869338

Group type: EXPERIMENTAL
Intervention: DNA-prime, pox virus boost strategy vaccination
Number of subjects: 0
Study: 29059389

Group type: EXPERIMENTAL
Intervention: IMB model-based intervention plus nicotine replacement therapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Facilitated referral to the state Quitline (Control)
Number of subjects: 83
Study: 27010951

Group type: EXPERIMENTAL
Intervention: Physician manager education about hypertension management
Number of subjects: 103
Study: 25193393

Group type: EXPERIMENTAL
Intervention: Polypill (containing aspirin 100 mg, simvastatin 40 mg, and ramipril 2.5, 5, or 10 mg)
Number of subjects: 695

Group type: COMPARATOR
Intervention: 3 drugs given separately (control group)
Number of subjects: 695
Study: 22525485

Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl nitrate (GTN) 0.4 mg
Number of subjects: 10
Study: 20541170

Group type: EXPERIMENTAL
Intervention: Pelvic radiation (75 Gy) plus hysterectomy (RTH)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Pelvic radiation (75 Gy) and cisplatin (40 mg/m2) plus hysterectomy (RTCH)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Good response patients (345; 74%) after RTH or RTCH
Number of subjects: 464
Study: 17562035

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination (CM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tracking Training (TR)
Number of subjects: 20
Study: 17165335

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with human amniotic membrane (HAM)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with mitomycin C (MMC)
Number of subjects: 28
Study: 12187222

Group type: EXPERIMENTAL
Intervention: Transurethral prostate resection
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Electrovaporization
Number of subjects: 141
Study: 10192668

Group type: EXPERIMENTAL
Intervention: Topical anesthetics and vasoconstrictors (phenylephrine 0.5%, 2% lidocaine jelly, 2% tetracaine, 14% benzocaine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (surgical lubricants only)
Number of subjects: 40
Study: 7590720

Group type: EXPERIMENTAL
Intervention: Clindamycin 2% cream (5 grams daily for 3 days)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 221
Study: 1969992

Group type: EXPERIMENTAL
Intervention: No-scalpel vasectomy
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Standard incisional vasectomy
Number of subjects: 1203
Study: 91481

Group type: COMPARATOR
Intervention: 4 g L-tryptophan
Number of subjects: 6
Study: 31033430

Group type: EXPERIMENTAL
Intervention: Knowledge, Attitude and Practice (KAP) regarding occupational noise exposure; scores above 75% defined as good knowledge and positive attitude, scores >50% defined as good practice.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Provision of hearing protection devices.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Hearing conservation program implementation.
Number of subjects: 253
Study: 31719084

Group type: EXPERIMENTAL
Intervention: Lifestyle Africa intervention (17 weekly sessions delivered by trained community health workers, including text messaging and Motivational Interviewing training)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 28